Marcela V. Maus, M.d.,ph.d.

This early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for adults with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The main goals are to check safety and find the best dose…

This early-phase study tests a new treatment called CARv3-TEAM-E T cells for people with glioblastoma, a fast-growing brain cancer that has come back. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack the tumor. The main goals are to …

This early-phase study tests a new treatment called CC-97540 for people with severe ANCA-associated vasculitis that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy disease-causing cells. The main goal is to …

This study tests whether the drug emapalumab can prevent severe cytokine release syndrome (CRS), a common and serious side effect of CAR-T cell therapy. It enrolls 28 adults with certain types of relapsed or refractory large B-cell lymphoma who are receiving standard CAR-T treatm…

This early-phase study tests a new treatment called TriPRIL CAR T cells for people with multiple myeloma that has come back or not responded to standard therapy. The main goal is to check safety and side effects in 18 adults. Participants first receive chemotherapy to prepare the…